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Abstract
Dengue virus is a single-stranded, enveloped RNA virus that productively infects human dendritic cells (DCs) primarily at the immature stage of their differentiation. We now find that all
four serotypes of dengue use DC-SIGN (CD209), a C-type lectin, to infect dendritic cells.
THP-1 cells become susceptible to dengue infection after transfection of DC-specific ICAM-3
grabbing nonintegrin (DC-SIGN), or its homologue L-SIGN, whereas the infection of dendritic cells is blocked by anti–DC-SIGN antibodies and not by antibodies to other molecules
on these cells. Viruses produced by dendritic cells are infectious for DC-SIGN– and L-SIGN–
bearing THP-1 cells and other permissive cell lines. Therefore, DC-SIGN may be considered
as a new target for designing therapies that block dengue infection.
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Introduction
Dengue virus (DV)* is the most common human arbovirus
infection worldwide. It is an emerging and volatile public
health concern. DV is composed of four antigenically distinct serotypes: DV 1, 2, 3, and 4 (1). All serotypes cause
human disease; viremia is detected early, in essentially all
DV cases at the onset of symptoms (2). Although most infections are generally mild, a complicated DV infection can
result in dengue hemorrhagic fever and dengue shock syndrome. These life-threatening complications usually occur
after a second DV infection with a heterologous strain (3).
R.M. Steinman, S. Schlesinger, and M.A. Marovich all contributed
equally to this work.
Address correspondence to Mary A. Marovich, 13 Taft Ct., Suite 200,
Rockville, MD 20850. Phone: 301 251-8337; Fax: 301 762-4177;
E-mail: mmarovich@hivresearch.org
*Abbreviations used in this paper: DC, dendritic cell; DC-SIGN, DCspecific ICAM-3 grabbing nonintegrin; DV, dengue virus; HIV-1, HIVtype 1; ICAM, intracellular adhesion molecule; L-SIGN, liver/lymph
node–specific ICAM-3–grabbing nonintegrin; MCM, monocyte-conditioned media; MFI, mean fluorescence intensity; MOI, multiplicity of infection; NS1, nonstructural protein 1; THP DC-SIGN, DC-SIGN–
transfected THP.
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Epidemiologic evidence indicates that the immune-mediated enhancement of infection in the presence of a waning
heterologous antibody is the underlying mechanism (4, 5).
This process is referred to as antibody-dependent enhancement and was first reported over 30 yr ago (6, 7). The
phenomenon of antibody-dependent enhancement notwithstanding, the fact remains that no long-term cross protection is conferred by any dengue serotype (8). This makes
the prospects of vaccine design demanding and creates an
impetus for new types of therapy.
The design of strategies to counter DV infection requires
information on cellular sites and mechanisms of infection.
However, limited data are available to establish the major
sites of DV replication in vivo. In natural infection, DV is
deposited by the mosquito vector into the skin during a
blood meal. Recent studies (9–12) indicate that immature
dendritic cells (DCs), which are normal residents of the
skin, support infection with DV, and that this infection is
not altered by a DV-enhancing immune serum (10). Cellular receptors for DV also are not well-defined. Heparan sulfates (13), LPS/CD14-associated binding proteins (14), and
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Materials and Methods
Viral Stocks and Infection. All viral stocks and cell lines were
mycoplasma-free. The dengue-2 strain, S16803, was grown in an
African green monkey Vero cell line (American Type Culture
Collection), and cell-free supernatants with a titer of 106–107
PFU/ml were used as virus stocks. In some experiments, DV 1,
3, and 4 from two sources were also used. The isolates were either nonattenuated (not passaged in primary dog kidney cells) and
grown in the lab in C6/36 mosquito cells and Vero cells, or the
viruses were low passage clinical isolates from Bandung, Indonesia and grown in C6/36 mosquito cells after isolation. For DV infection, the cells were exposed to DV for 2 h with a multiplicity
of infection (MOI) of 0.02–1. The exposed cells were washed
with a complete medium (cRPMI consisting of RPMI 1640
[Quality Biologicals] supplemented with 10% heat-inactivated
FCS [PAA Laboratories, Inc.], 2 mM l-glutamine, 100 U/ml
penicillin, and 100 U/ml streptomycin [Quality Biologicals]) at
least twice to remove excess virus. For antibody-blocking studies, we tested azide-free anti–human-DC-SIGN1 mAb (clone
120507), anti–DC-SIGN2 (clone 120612), anti–L-SIGN (clone
120604; R&D Systems), anti-CD11a (lymphocyte function–associated antigen 1, LFA-1), anti-CD58 (LFA-3), anti-CD74 (invariant chain), and matched isotype controls (Becton Dickinson).
The test cells were pretreated with 2–20 µg/ml of the indicated
mAb for 60 min at 37C before exposure to DV.
Monocyte-derived DCs. PBMCs were cultured as described
previously (29) with some modifications. In brief, leukapheresis
blood from healthy donors was layered over Ficoll-Hypaque and
centrifuged to isolate the mononuclear cells, which were adhered
to Petri dishes for 60 min at 37C. After six to eight washes with
complete media, the adherent cells were cultured in 10 ml
cRPMI with 800 U/ml rhuGM–CSF (Immunex) and 1,000
U/ml rhuIL-4 (R&D Systems). Cytokines were added every
other day. To produce mature DCs, 20% (vol/vol) monocyteconditioned media (MCM) was added to the cells for an additional 2 d. MCM was prepared as described previously (29). The

824

appropriate phenotype of immature and mature DCs was confirmed by cytofluorometry before each experiment. Specifically,
immature and mature DCs lacked CD3, CD14, CD20, and
CD56, but expressed high levels of MHC class I, class II, and
CD1a; only mature cells expressed high levels of CD25, CD83,
and CD86 as described previously (30).
THP-1 Human Monocytic Cell Lines. We were provided
with DC-SIGN–transfected THP-1 (THP DC-SIGN), THP
DC-SIGN 35 (fully truncated cytoplasmic tail), and THP-1
cells by Dr. D. Littman (New York University School of Medicine, New York, NY; reference 27) and L-SIGN/DC-SIGNR
expressing THP (THP L-SIGN) by Dr. V. KewalRamani (National Cancer Institute, Frederick, MD; reference 25). All THP-1
cells were grown in complete media.
Monitoring Infection with DV. The DV or mock-infected cells
were cytospun onto slides, air-dried, and fixed with 4% paraformaldehyde. Specific anti–DV mAbs, 2H2, or 3H5 (anti–DV envelope complex) or anti–DC-SIGN (120507) were applied after
permeabilization with 1% saponin. After several washes, the appropriate secondary antibodies were added; i.e., for immunofluorescence, directly conjugated goat anti–mouse Alexa Fluor 546 or
488 (Molecular Probes) or for immunocytochemistry, biotinylated horse anti–mouse followed by Vectastain ABC alkaline
phosphatase or peroxidase kits (Vector Labs). Nuclei were labeled
with DAPI (4, 6-diamidino-2-phenylindole  2HCl; SigmaAldrich) for immunofluorescence. Matched isotype control antibodies were used in both mock-infected and DV–exposed cells to
assess background staining. The slides were mounted and analyzed using either standard light microscopy or a deconvolution
microscope (AX-70 laser scanning microscope; Olympus). To
quantify the infection virus, a Vero cell plaque assay was performed as described previously (31). Six 10-fold serial dilutions
(1:10–1:106) were made for each supernatant sample and inoculated
into duplicate wells of six-well tissue culture plates containing
confluent Vero cell monolayers. After virus adsorption for 1 h,
the Vero monolayers were overlaid with complete MEM media
(Cellgro) containing agarose (Invitrogen) to restrict dissemination
of progeny virions. The cells were incubated for 5 d at 37C in a
5%-CO2 incubator and overlaid with the vital stain, neutral red
(Sigma-Aldrich). Plaques were counted by visual inspection at 24
and 48 h after neutral red overlay to determine the number of
plaque-forming units of DV per milliliter of supernatant.
Flow Cytometry. To characterize DCs, a FACS® Calibur
(Becton Dickinson) was used to monitor surface staining with a
panel of PE-conjugated mAbs to HLA-DR, CD80, CD86, CD3,
CD14, CD20, CD25 (Becton Dickinson), CD83 (Immunotech),
CD11c, CD1a (BD Biosciences), and matched isotype controls.
To detect intracellular DV antigens, cells were fixed with 4%
paraformaldehyde, permeabilized with 0.5% saponin, stained
with FITC-conjugated–2H2 (anti–DV envelope complex mAb)
and/or FITC-conjugated–7E11 (anti–DV-NS1 mAb, first nonstructural protein), with antibodies provided by R. Putnak
(Walter Reed Army Institute of Research, Washington, DC).
Statistical Analysis. This was performed with StatView 5
(SAS Institute).

Results
Cell-surface DC-SIGN Expression Correlates with DV Infection Rates. We used flow cytometry to follow the expression of DC-SIGN and infection with DV. We suspected that DC-SIGN (CD209) might serve as a DV
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other glycoproteins (15, 16) have been proposed as cellular
receptors for DV, but these would not explain our prior
findings (9) that DCs and not monocytes or macrophages
are preferentially infected with DV.
Certain subsets of DCs, especially those susceptible to infection with DV in culture (9–12), express DC-specific intracellular adhesion molecule (ICAM) 3–grabbing nonintegrin (DC-SIGN; reference 17). This C-type lectin allows
direct infection of DCs with Ebola virus (18, 19), human
cytomegalovirus (20), Leishmania pifanoi amastigotes (21),
and Mycobacterium tuberculosis (22–24). DC-SIGN also accounts, in large part, for the capacity of DCs to capture and
retain HIV-type 1 (HIV-1) for the infection of T cells (17,
25–28). Using primary human DCs naturally expressing
DC-SIGN, as well as cell lines transfected with DC-SIGN
and its homologue liver/lymph node–specific ICAM-3–
grabbing nonintegrin (L-SIGN), we show extensive infection with DV as a direct result of expression of these lectins. Because DC-SIGN–mediated DV entry allows for
productive infection, releasing infectious virions capable of
transmitting DV infection to susceptible cells, these results
make DC-SIGN a logical new candidate for interrupting
DV infection in humans.

Figure 1. Cytofluorometry of DV infection of DC-SIGN–expressing
cells. (A) The MFI of DC-SIGN surface expression on DC and THP-1
cells is shown (left). The bars represent means ( SEM) of at least three
independent experiments. The top right histogram shows the relative
DC-SIGN expression (MFI) on a representative donor’s immature
(shaded) and MCM-matured DCs (heavy line). The bottom right histogram shows relative DC-SIGN on the surface of THP DC-SIGN
(shaded) and THP-1 cells (heavy line). Matched isotype controls are represented by the light dashed line. (B) The mean ( SEM) percentage of
DV infection of immature and mature DC (left) and THP DC-SIGN and
THP-1 (right) after intracellular staining for dengue envelope antigen
(2H2) in at least three independent experiments. (C) Positive correlation
between DC-SIGN expression (MFI) on the x axis and percent DV infection as determined by 2H2 binding on the y axis on both DC and
THP cells (n  16).
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and no DC-SIGN expression on the nontransfected cells
(Fig. 1 A). When these different cell types were exposed to
DV (MOI  1) and evaluated for infection 48 h later using
a DV-specific monoclonal antibody (2H2) that binds to a
dengue envelope complex protein, only the DCs and the
THP DC-SIGN transfectants were infected (Fig. 1 B). In
multiple experiments, the amount of infection of each cell
type was directly correlated (r  0.89) with the level of
DC-SIGN expression (Fig. 1 C). These data implicate DCSIGN in DV infection.
THP DC-SIGN Can Be Infected with All Four Serotypes
of DV. We extended the study of DV infection to two
different DV-specific monoclonal antibodies, the previously
mentioned 2H2 anti–envelope complex antibody and the
7E11 antibody, to a nonstructural protein 1 (NS1) that is
expressed during viral replication but is not a component of
the virion. Infection, as assessed by the binding of monoclonal antibodies, was proportional to the dose of added virus (Fig. 2 A). The 2H2 binding typically was slightly
higher than the 7E11 binding and again, no infection was
detected in the nontransfected THP with either antibody.
Kinetic studies with the DEN-2 virus (MOI  0.2) were
used to determine the peak time for detection of infection
(Fig. 2 B). The optimal time point was at 48 h after viral
exposure, which is consistent with previous studies in primary DCs (9, 11, 12). All studies used this 48-h time point,
unless otherwise noted. All four DV serotypes were able to
infect THP DC-SIGN transfectants, as previously shown in
immature DCs (Fig. 2 C; reference 9). Of note, both low
passage clinical isolates (two passages) and more lab-adapted
isolates were able to infect at similar levels. When DV infection was evaluated in THP cells transfected with
L-SIGN, a close relative of DC-SIGN (25), high levels of infection were again observed with all four serotypes (unpublished data). To inspect DV infection at the cellular level,
we looked for DV antigens (2H2; red) using immunofluorescence and confocal microscopy in DC-SIGN–bearing
cells (Fig. 2 D, green) at early and late time points, 2 and
24 h, respectively (Fig. 2 D). Newly produced virions accumulated in both DCs and THP transfectants at the later
time point (Fig. 2 D, bottom), which is consistent with
prior EM observations that replicating DV (at 24–48 h) is
found in the endoplasmic reticulum of DCs (9, 12). The
presence of the replicating virus within the DC-SIGN–
bearing cells was confirmed by staining viral antigens with
2H2, using immunohistochemistry techniques. Abundant
viral antigen was noted in the cytoplasm (Fig. 2 E, red) in
DC-SIGN–bearing cells (Fig. 2 E, blue) at 48 h (but not at
2 h) for both immature DC and THP DC-SIGN (Fig. 2 E)
and THP L-SIGN (unpublished data). No viral antigens
were detected in non DC-SIGN–bearing cells (unpublished data). Therefore, transfection of THP cells with DCSIGN and L-SIGN renders the cells permissive to infection
with all DV serotypes.
Anti–DC-SIGN Monoclonal Antibodies Block DV Infection
in Dendritic Cells and THP DC-SIGN Cells. To further
evaluate DC-SIGN as a potential DV receptor, we used
two different anti–DC-SIGN antibodies (clones 120612
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receptor. For example, prior work showed that immature
DCs were much more susceptible to DV infection than
their mature counterparts (5–10-fold higher levels; reference 9), and we found that the expression of DC-SIGN
mean fluorescence intensity (MFI) was threefold higher on
immature DCs (MFI  175  49, n  4) compared with
mature DCs (MFI  60  3, n  3; Fig. 1 A) in agreement with other reports (18, 27, 32, 33). To study the role
of DC-SIGN in DV entry, we used a DC-SIGN–transfected THP-1 (THP DC-SIGN) cell line, and the corresponding nontransfected THP cells as controls (27). We
confirmed high levels of DC-SIGN on the transfected cells

and 120507). Preliminary antibody titration experiments
were performed, which indicated that a range of 2–20 µg/
ml antibody was sufficient to reduce infection of the DC
(unpublished data). All subsequent blocking experiments
were conducted using 2 µg/ml anti–DC-SIGN antibody
and matched isotype control antibodies including antiCD11a. In multiple experiments, both DC-SIGN antibodies independently and significantly blocked DV infection of
either immature or mature DCs at 2 µg/ml (Fig. 3 A). We
used similar experimental conditions for blocking DV infection of THP cells (Fig. 3 B). We added two other relevant antibodies that react strongly with the cells: antiCD58 (LFA-3) and anti-CD74 (invariant chain). The levels
of DV infection were unaltered in the presence of antibodies to CD58, CD74, or CD11a. Interestingly, we found
that the 120507 clone was less effective at blocking DV in826
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Figure 3. Blocking studies of DV infection in DCs and THP-1. (A)
Comparison of percent DV2 infection rate of immature (left) and mature
DCs (right) in the presence and absence of anti–DC-SIGN mAbs (clones
120507-specific or 120612–cross-reactive), anti-CD11a, or an irrelevant
matched isotype control. (B) Comparison of percent DV2 infection rate
of THP DC-SIGN and THP-1 in the presence and absence of specific
anti–DC-SIGN mAbs, anti-CD11a, anti-CD58, anti-CD74, or an irrelevant matched isotype control. Data are means ( SEM) of four independent experiments. (C) A representative blocking experiment (one of two)
in the THP L-SIGN cells in the presence and absence of specific anti–
DC-SIGN or L-SIGN mAbs (120604), anti-CD11a, or an irrelevant
matched isotype control.

fection (reduced by 50%) when compared with the “crossreactive” 120612 clone (reduced by 90%) in the THP DCSIGN cells. The THP L-SIGN cells were readily blocked
using either the cross-reactive clone 120612 (75% reduction) or the L-SIGN–specific clone 120604 (95% reduction; Fig. 3 C). Thus, DV infection of DCs, DC-SIGN, or
L-SIGN–transfected cells can be significantly blocked by
antibody-selective targeting of an epitope shared by DCSIGN and L-SIGN.
The Cytoplasmic Domain of DC-SIGN Enhances but Is Not
Essential for Infection. To gain information on the mechanism of DC-SIGN function, we considered a THP DCSIGN cell line in which the DC-SIGN molecule lacked its
cytoplasmic domain (THP DC-SIGN 35). The cytosolic
tail of DC-SIGN mediates endocytosis and is important for
sequestering and transmitting HIV-1 when DCs are exposed to low doses of virus (27). DC-SIGN expression levels on the wild-type and THP DC-SIGN 35 cells were
comparable (300–500 MFI). We found a significant reduction in viral entry in the THP DC-SIGN 35 (75% reduc-
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Figure 2. Dose and time dependence of DV infection in THP DCSIGN cells. (A) Titration of DV2 infection in THP DC-SIGN and THP-1
2 d after infection. The infected cells were stained for DV envelope antigen (clone 2H2) and the NS1 (clone 7E11) and infection was determined
by calculating the percentage of fluorescence-positive cells. (B) Kinetics
of DV2 infection in THP DC-SIGN and THP-1. The infected cells were
harvested at t  0, 24, 48, and 72 h and stained with 2H2 and 7E11. (C)
DV infection rates of all four DV serotypes in THP DC-SIGN and
THP-1, using DV 1, 2, 3, and 4. Data are averages of two independent
experiments. (D) Representative immunofluorescence experiment at two
time points (2 h, top, and 24 h, bottom) showing bound DV envelope
complex antigens (red) in DC-SIGN (green)–bearing DC (left) and
THP-DC-SIGN (right) cells. Nuclei were labeled with DAPI stain. (E)
Representative immunohistochemistry experiment showing bound intracellular DV envelope complex antigens (dark red) in DC-SIGN–bearing
cells (blue). The left (immature DC) and right panels (THP DC-SIGN)
show cells infected with DV. Original magnifications at 200 (insets, 600).

tion) after DV exposure (Fig. 4). Nevertheless, the residual
DV infection could be completely abrogated in the presence of the anti–DC-SIGN antibody (clone 120612). This
residual infection might have resulted from the constitutive
entry of the truncated DC-SIGN receptor during bulk
phase endocytosis, which is active in the cells we studied.
Spreading Infection of DCs Is Inhibited by Anti–DC-SIGN
Antibodies. To determine if DV infection of DCs produced infectious virions, we performed a standard DV
plaque assay (31) in susceptible Vero cells. We infected
DCs or THP DC-SIGN/THP L-SIGN cells for 2 h in the
absence or presence of blocking anti–DC-SIGN mAbs,
washed, cultured the cells for 48 h to allow for production
of infectious virus, and checked the 48-h supernatants for
infection of Vero cells. The data showed that supernatants
from the DC-SIGN–bearing cells induced plaque formation and transmitted DV infection; furthermore, the
“trans” DV infection was significantly reduced (1 log
drop [PFU/ml]) when the initial infection of DCs had
been performed in the presence of anti–DC-SIGN antibodies (Fig. 5).

Discussion
This paper identifies DC-SIGN and L-SIGN as mediators of DV infection. DC-SIGN is expressed primarily by a
subset of DCs, whereas L-SIGN is expressed by certain endothelial cells, especially sinusoidal endothelium in liver
and lymphoid organs and placental capillaries. We suggest
that DC-SIGN allows immature DCs to capture and replicate DV after transmission from the mosquito vector. It is
not clear if standard targets for DV infection, e.g., monkey
Vero cells and C6/36 mosquito cells, express a functionally
equivalent molecule to DC-SIGN or if they use an entirely
distinct pathway of infection.
Although DC-SIGN binds at least two normal cellular
adhesion molecules, ICAM-3–CD50 (32) and ICAM-2–
CD102 (34), much of the research on this C-type lectin has
involved its interaction with pathogens. DC-SIGN is proving to be a receptor used by DCs to capture, replicate, and/
or transmit many pathogens, at least in culture. DC-SIGN
is known to play a critical role in tissue culture by enhancing HIV transmission from DC to T cells (17, 27, 35). Recently, the Ebola virus (18, 19), cytomegalovirus (20), L.
pifanoi amastigotes (21), and M. tuberculosis (22–24) were
shown to use DC-SIGN to gain entry into DCs. Not only
are large numbers of DCs and transfected THP-1 cells in827
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Figure 5. Plaque assays of cell-free culture supernatants show infectivity. Supernatants transmit DV infection from DV-infected DCs (left) and
THP DC-SIGN cells (right) to Vero cells. DCs or THPs were pretreated
with an anti–DC-SIGN mAb (clone 120612) or a matched isotype control and exposed to DV for 2 h. Virus and mAb were washed away, and
the supernatants were collected 48 h later. Plaque assays were used to determine PFUs in the collected supernatants. Data are the averages of two
independent experiments.

fected quickly with DV, but these cells yield a virus that is
infectious for other cells. Thus, very low MOIs are sufficient to bring about a productive infection. In HIV-1 infection, direct infection of DCs is actually minimal at a
time that DC-SIGN is allowing the DCs to sequester and
transmit HIV-1 to T cells. With cytomegalovirus, like DV,
the DCs themselves are infected (cis) and enhance infection
of a permissive cell type in trans (20); in Ebola, L. pifanoi,
and M. tuberculosis, it remains to be determined if DCSIGN promotes spreading infection. Therefore, DC-SIGN
likely recognizes “pathogen-associated microbial patterns.”
One of the consequences of the DC-SIGN–pathogen interaction may be to enhance infection or pathogenesis by
allowing the pathogen to enter the endocytic system. Once
inside the endocytic pathway, the pathogen either replicates or fuses with the vacuole membrane to enter the cytoplasm. The latter is proposed for a pathogen like DV,
where an acidic environment is likely to be required for the
fusion of the DV envelope glycoproteins with the host cell
membrane (36).
We used specific monoclonal Abs to block infection of
DCs and THP DC-SIGN/L-SIGN to prove that viral entry depends specifically on these lectins. Control antibodies
that reacted strongly with DCs and THPs (CD11a, 58, and
74) did not block infection. The two receptors, DC-SIGN
and L-SIGN/DC-SIGNR, exhibit 77% amino acid identity and likely share ligands (25). We used two anti–DCSIGN clones: DC-SIGN–specific (120507) and another
cross-reactive clone (120612) that binds to shared epitopes
on DC-SIGN and L-SIGN/DC-SIGNR. The antibodies
all blocked infection in primary DCs and THP DC-SIGN,
but the latter were most efficiently blocked with the crossreactive monoclonal antibody. This suggests that a critical
epitope for DV infection involves an epitope shared by
DC-SIGN and L-SIGN. However, this does not exclude
other possibilities such as antibody-induced steric hindrance of a nearby DV epitope or antibody-induced conformational changes at a distant epitope.
In an extension of the work presented here, we performed neutralization assays with sera from DV-infected
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Figure 4. Internalization of
DV. Comparison of DV infection of THP DC-SIGN, THP
DC-SIGN 35 (fully truncated
cytoplasmic domain DC-SIGN),
and THP-1 in the presence of
specific anti–DC-SIGN antibody
(clone 120612) or a matched isotype control. Data are the mean
( SEM) of three independent
experiments.
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